^
Association details:
| Biomarker: | IDH2 mutation |
|---|---|
| Cancer: | Peripheral T-cell Lymphoma |
| Drug: | Aliqopa (copanlisib) (PIK3CA inhibitor, PI3Kδ inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
COMBINATION TREATMENT WITH COPANLISIB, A PI3K INHIBITOR, AND GEMCITABINE IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS (RR-PTCL); A MULTICENTER, OPEN-LABEL, PHASE 1/2 TRIAL (COSMOS TRIAL)
Published date:
06/12/2020
Excerpt:
All received at least one cycle of Cop/Gem combination at the dose of 45 mg (N=3) and 60 mg (N=25) of Cop....All the 28 pts were evaluable for efficacy and the ORR was 71.4% (20/28) with a complete response (CR) rate of 32.1% (Fig 1A). Cop/Gem combination was substantially more active in pts with AITL...The genes exclusively mutated in the responsive group were IDH2, RHOA, and TSC2.
Secondary therapy:
gemcitabine
Trial ID:
